Astrazeneca (AZN) Current Assets (2009 - 2026)

Astrazeneca's Current Assets history runs 18 years deep, the most recent figure standing at $29.6 billion for Q1 2026.

• In Q1 2026, Current Assets rose 13.29% year-over-year to $29.6 billion; the TTM figure through Mar 2026 stood at $29.6 billion (up 13.29% YoY), while the FY2025 annual figure was $28.7 billion, up 11.21% from the prior year.
• Current Assets was $29.6 billion for Q1 2026 at Astrazeneca, up from $28.7 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $29.9 billion in Q3 2025 to a low of $20.2 billion in Q3 2022.
• Historically, Current Assets has averaged $24.9 billion across 5 years, with a median of $25.1 billion in 2023.
• Biggest YoY gain for Current Assets was 52.99% in 2022; the steepest drop was 24.23% in 2022.
• A 5-year view of Current Assets shows it stood at $22.6 billion in 2022, then grew by 10.89% to $25.1 billion in 2023, then grew by 3.09% to $25.8 billion in 2024, then grew by 11.21% to $28.7 billion in 2025, then grew by 3.1% to $29.6 billion in 2026.
• The last three Current Assets figures came in at $29.6 billion (Q1 2026), $28.7 billion (Q4 2025), and $29.9 billion (Q3 2025), per Business Quant data.